T Mark Doherty

Summary

Affiliation: Statens Serum Institut
Country: Denmark

Publications

  1. pmc Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis
    Abebech Demissie
    Armauer Hansen Research Institute, Addis Ababa, Ethiopia
    Clin Vaccine Immunol 13:179-86. 2006
  2. pmc Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over time
    Liya Wassie
    Armauer Hansen Research Institute, Addis Ababa, Ethiopia
    PLoS ONE 3:e1522. 2008
  3. pmc Modulation of cell death by M. tuberculosis as a strategy for pathogen survival
    Markos Abebe
    Armauer Hansen Research Institute, PO Box 1005, Addis Ababa, Ethiopia
    Clin Dev Immunol 2011:678570. 2011
  4. pmc Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients
    T Mark Doherty
    Department of Tuberculosis Immunology, Statens Serum Institute Hvidovre Hospital, Copenhagen, Denmark
    J Clin Microbiol 40:704-6. 2002
  5. ncbi request reprint Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR
    T Mark Doherty
    Department of Tuberculosis Immunology, Statens Serum Institute, Copenhagen, Denmark
    J Immunol Methods 298:129-41. 2005
  6. ncbi request reprint Real world TB vaccines: clinical trials in TB-endemic regions
    T Mark Doherty
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    Vaccine 23:2109-14. 2005
  7. ncbi request reprint Tuberculosis subunit vaccines: from basic science to clinical testing
    T Mark Doherty
    Statens Serum Institute, Department of Infectious Disease Immunology, Copenhagen, Denmark
    Expert Opin Biol Ther 7:1539-49. 2007
  8. ncbi request reprint Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis
    T Mark Doherty
    Department of Infectious Disease Immunology, Statens Seruminstitut, Copenhagen, Denmark
    J Infect Dis 190:2146-53. 2004
  9. ncbi request reprint Biomarkers for tuberculosis disease status and diagnosis
    Mark Doherty
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    Curr Opin Pulm Med 15:181-7. 2009
  10. ncbi request reprint New vaccines against tuberculosis
    T Mark Doherty
    Department of TB Immunology, Statens Serum Institute, Copenhagen, Denmark
    Trop Med Int Health 9:818-26. 2004

Collaborators

Detail Information

Publications38

  1. pmc Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis
    Abebech Demissie
    Armauer Hansen Research Institute, Addis Ababa, Ethiopia
    Clin Vaccine Immunol 13:179-86. 2006
    ....
  2. pmc Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over time
    Liya Wassie
    Armauer Hansen Research Institute, Addis Ababa, Ethiopia
    PLoS ONE 3:e1522. 2008
    ....
  3. pmc Modulation of cell death by M. tuberculosis as a strategy for pathogen survival
    Markos Abebe
    Armauer Hansen Research Institute, PO Box 1005, Addis Ababa, Ethiopia
    Clin Dev Immunol 2011:678570. 2011
    ..tuberculosis infection...
  4. pmc Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients
    T Mark Doherty
    Department of Tuberculosis Immunology, Statens Serum Institute Hvidovre Hospital, Copenhagen, Denmark
    J Clin Microbiol 40:704-6. 2002
    ..We report that strong recognition of tuberculosis complex-specific antigen ESAT-6 by healthy household contacts of tuberculosis patients correlates with the subsequent development of active tuberculosis during a 2-year follow-up period...
  5. ncbi request reprint Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR
    T Mark Doherty
    Department of Tuberculosis Immunology, Statens Serum Institute, Copenhagen, Denmark
    J Immunol Methods 298:129-41. 2005
    ..Researchers should carefully consider these factors when planning human field studies...
  6. ncbi request reprint Real world TB vaccines: clinical trials in TB-endemic regions
    T Mark Doherty
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    Vaccine 23:2109-14. 2005
    ..tuberculosis infection is expanding rapidly. This review summarizes the developing consensus on the BCG vaccine and its limitations and discusses clinical trials of some of the new vaccines intended to supplement or replace it...
  7. ncbi request reprint Tuberculosis subunit vaccines: from basic science to clinical testing
    T Mark Doherty
    Statens Serum Institute, Department of Infectious Disease Immunology, Copenhagen, Denmark
    Expert Opin Biol Ther 7:1539-49. 2007
    ..The challenges that confront these approaches and how they are being addressed are then discussed...
  8. ncbi request reprint Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis
    T Mark Doherty
    Department of Infectious Disease Immunology, Statens Seruminstitut, Copenhagen, Denmark
    J Infect Dis 190:2146-53. 2004
    ....
  9. ncbi request reprint Biomarkers for tuberculosis disease status and diagnosis
    Mark Doherty
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    Curr Opin Pulm Med 15:181-7. 2009
    ..As a result, recent years have seen the initiation of large-scale studies aiming to identify biomarkers of Mycobacterium tuberculosis infection and disease. This review discusses initial results and future prospects for that work...
  10. ncbi request reprint New vaccines against tuberculosis
    T Mark Doherty
    Department of TB Immunology, Statens Serum Institute, Copenhagen, Denmark
    Trop Med Int Health 9:818-26. 2004
    ..This review summarizes recent advances in tuberculosis vaccine development, with a special emphasis on issues raised at the Gorée meeting about testing and deploying new generation vaccines in TB-endemic areas such as Africa...
  11. ncbi request reprint Tuberculosis vaccine development
    T Mark Doherty
    Department of Tuberculosis Immunology, Statens Serum Institut, Copenhagen, Denmark
    Curr Opin Pulm Med 8:183-7. 2002
    ..This selection is being eased by the improved animal models that have been developed over the past few years and by our increasing understanding of immunity to TB...
  12. pmc Vaccines for tuberculosis: novel concepts and recent progress
    T Mark Doherty
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    Clin Microbiol Rev 18:687-702. 2005
    ..This provides a background for describing the new generation of vaccines designed to supplement or replace the current vaccine and the different approaches they take to stimulate immunity against M. tuberculosis...
  13. doi request reprint Biomarkers of disease activity, cure, and relapse in tuberculosis
    T Mark Doherty
    Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, 2300 København S, Denmark
    Clin Chest Med 30:783-96, x. 2009
    ..As a result, research aiming to identify biomarkers of Mycobacterium tuberculosis infection and disease has flourished. This article discusses the most recent findings of that work...
  14. ncbi request reprint Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity
    Jes Dietrich
    Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, DK 2300 Copenhagen, Denmark
    J Immunol 177:6353-60. 2006
    ..tb in LTK63/Ag85B-ESAT-6-boosted mice, compared with BCG-vaccinated animals. Thus, LTK63/Ag85B-ESAT-6 represents an efficient preventive vaccine against tuberculosis with a strong ability to boost prior BCG immunity...
  15. pmc The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon
    Abebech Demissie
    Armauer Hansen Research Institute, Addis Ababa, Ethiopia
    Infect Immun 74:2817-22. 2006
    ....
  16. ncbi request reprint Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis
    Thomas Bennekov
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    Eur J Immunol 36:3346-55. 2006
    ....
  17. ncbi request reprint Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2
    Abebech Demissie
    Armauer Hansen Research Institute, Addis Ababa, Ethiopia
    J Immunol 172:6938-43. 2004
    ..These data suggest that long-term control of M. tuberculosis infection is associated not just with elevated Th1 responses but also with inhibition of the Th2 response...
  18. pmc Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis
    T Mark Doherty
    Department of Tuberculosis Immunology, Statens Serum Institute, Copenhagen, Denmark
    Infect Immun 70:3111-21. 2002
    ....
  19. ncbi request reprint Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy
    Jes Dietrich
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    J Immunol 174:6332-9. 2005
    ..4, we show that ESAT-6, apart from being an excellent diagnostic reagent, can also be used as a reagent for monitoring vaccine efficacy. This may open a new way for monitoring vaccine efficacy in clinical trials...
  20. doi request reprint Expression of apoptosis-related genes in an Ethiopian cohort study correlates with tuberculosis clinical status
    Markos Abebe
    Armauer Hansen Research Institute, Addis Ababa, Ethiopia
    Eur J Immunol 40:291-301. 2010
    ..tuberculosis. This may represent an important survival strategy for the pathogen...
  21. ncbi request reprint The prognosis of latent tuberculosis: can disease be predicted?
    Peter Andersen
    Statens Serum Institut, Department of Infectious Disease Immunology, Artillerivej 5, DK 2300 Copenhagen S, Denmark
    Trends Mol Med 13:175-82. 2007
    ..This might provide an unprecedented advantage for TB control, namely targeted preventive therapy for individuals who are most at risk of developing active contagious TB...
  22. ncbi request reprint Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection
    Jes Dietrich
    Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, Copenhagen, Denmark
    J Immunol 178:3721-30. 2007
    ..Thus, these studies suggest an immunization strategy where a novel TB subunit vaccine is administered as part of the child vaccination program together with BCG in neonates and followed by subunit boosting...
  23. pmc Assessing the serodiagnostic potential of 35 Mycobacterium tuberculosis proteins and identification of four novel serological antigens
    Karin Weldingh
    Department of Infectious Disease Immunology, Statens Serum Institut, Artillerivej 5, DK 2300 Copenhagen S, Denmark
    J Clin Microbiol 43:57-65. 2005
    ..3 and the TB9.7 antigens were recognized by more than 85% of the samples from TB patients coinfected with human immunodeficiency virus, a patient group for which it is in general difficult to detect M. tuberculosis-specific antibodies...
  24. doi request reprint Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development
    Jes Dietrich
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    APMIS 117:440-57. 2009
    ..In this review, we will discuss what is presently known about the interaction of M. tuberculosis with the immune system, and how this knowledge is used in new and more advanced vaccine strategies...
  25. ncbi request reprint The success and failure of BCG - implications for a novel tuberculosis vaccine
    Peter Andersen
    Statens Serum Institute, Department of Infectious Disease Immunology, Artillerivej 5, 2300 Copenhagen S, Denmark
    Nat Rev Microbiol 3:656-62. 2005
    ..Here, we discuss the potential mechanisms behind the variation of BCG efficacy and their implications for an improved TB vaccination strategy...
  26. pmc Diagnosis of latent tuberculosis infection in healthy young adults in a country with high tuberculosis burden and BCG vaccination at birth
    Alemnew F Dagnew
    Armauer Hansen Research Institute, Addis Ababa, Ethiopia
    BMC Res Notes 5:415. 2012
    ..The aim of this study was therefore to evaluate the use of QFT-GIT assay as compared with TST in the diagnosis of LTBI in Ethiopia, a country with a high burden of TB and routine BCG vaccination at birth...
  27. ncbi request reprint Progress and hindrances in tuberculosis vaccine development
    T Mark Doherty
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    Lancet 367:947-9. 2006
  28. ncbi request reprint TB subunit vaccines--putting the pieces together
    Peter Andersen
    Department of Infectious Disease Immunology, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen, Denmark
    Microbes Infect 7:911-21. 2005
    ..This requires carefully monitoring aspects as immunodominance, recognition in different populations as well as vaccine manufacturing...
  29. ncbi request reprint Evaluation of Mycobacterium tuberculosis--specific antibody responses in populations with different levels of exposure from Tanzania, Ethiopia, Brazil, and Denmark
    Soren T Hoff
    Department of Infectious Diseases Immunology, Statens Serum Institute, Copenhagen S, Denmark
    Clin Infect Dis 45:575-82. 2007
    ..A key question remaining is the extent to which the disappointing performance of current tests is associated with a high background prevalence of latent TB...
  30. ncbi request reprint Selecting the components for a safe and efficient tuberculosis subunit vaccine--recent progress and post-genomic insights
    Limei Meng Okkels
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    Curr Pharm Biotechnol 4:69-83. 2003
    ..In this review, we discuss how these new approaches have accelerated the pace of antigen discovery and vaccine development, and highlight some of the most promising new candidate vaccines and vaccine targets...
  31. doi request reprint Vaccines in a hurry
    Christian Søborg
    Statens Serum Institut, Copenhagen, Denmark
    Vaccine 27:3295-8. 2009
    ....
  32. doi request reprint TB vaccines: current status and future perspectives
    Claus Aagaard
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    Immunol Cell Biol 87:279-86. 2009
    ..Three such fusion proteins are currently in clinical trials, the two most advanced have already passed phase I trials and are entering phase II...
  33. pmc Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation
    Helen A Fletcher
    The Centre for Infectious Diseases and International Health, Windeyer Institute of Medical Sciences, Royal Free and University College Medical School, London, UK
    Immunology 112:669-73. 2004
    ..tuberculosis induces unusual, previously unrecognized, immunological events. We tentatively hypothesize that progression to active disease might depend upon the underlying ratio of IL-4 to IL-4delta2...
  34. pmc Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis
    Jean Michel Hougardy
    Laboratory of Vaccinology and Mucosal Immunity, Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 2:e926. 2007
    ..We have therefore evaluated the potential of the novel antigen heparin-binding hemagglutinin (HBHA) for in vitro detection of LTBI...
  35. ncbi request reprint The potential of recombinant antigens ESAT-6, MPT63 and mig for specific discrimination of Mycobacterium tuberculosis and M. avium infection
    Claudia Rolinck-Werninghaus
    Eur J Pediatr 162:534-6. 2003
  36. ncbi request reprint Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6
    Jan A M Langermans
    Department of Parasitology, Biomedical Primate Research Centre, P O Box 3306, 2280 GH Rijswijk, The Netherlands
    Vaccine 23:2740-50. 2005
    ..As far as we are aware this is the first report of protection in primates with a subunit vaccine...
  37. ncbi request reprint Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis
    Ann Williams
    Health Protection Agency, Porton Down, Salisbury SP4 OJG, UK
    Tuberculosis (Edinb) 85:29-38. 2005
    ..A relatively high aerosol-challenge dose and evaluation over a protracted time post-challenge allowed superior protection over BCG to be demonstrated by BCG boosted with MVA and fowl pox vectors expressing Ag85A...
  38. ncbi request reprint Mycobacterium avium complex promotes recruitment of monocyte hosts for HIV-1 and bacteria
    Hollie Hale-Donze
    Oral Infection and Immunity Branch, National Institute of Dental and Craniofacial Research, and Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 169:3854-62. 2002
    ..In vivo, opportunistic infection may act as a recruitment mechanism in which newly arrived monocytes serve as naive hosts for both MAC and HIV-1, thus perpetuating both infections...